In a phase I/II trial of patients with FLT3-ITD mutated AML treated with quizartinib plus azacitidine, the CR rate and median OS were promising at 87% and 19.2 months and 64% and 12.8 months in the frontline and R/R settings, respectively [61]. This evidence concerns the gene FLT3 and acute myeloid leukemia.